Identification of Hypoglycemia-dependent Endothelial Nitric Oxide Synthase O-GlcNAcylation Sites and Regulation of O-GlcNAcylation and Nitric Oxide Production by Hypoglycemia

CURRENT STATUS: POSTED

an he
Chongqing Medical University First Affiliated Hospital

heanaichirou@163.com

Corresponding Author

Shupeng Hu
Chongqing Medical University First Affiliated Hospital

Qiangzhong Pi
Chongqing Medical University First Affiliated Hospital

Yongzheng Guo
Chongqing Medical University First Affiliated Hospital

Yang Long
Chongqing Medical University First Affiliated Hospital

Suxin Luo
Chongqing Medical University First Affiliated Hospital

Yong Xia
Chongqing Medical University First Affiliated Hospital

DOI:
10.21203/rs.3.rs-22780/v1

SUBJECT AREAS
Cardiac & Cardiovascular Systems  Endocrinology & Metabolism

KEYWORDS
Hypoglycemia, eNOS O-GlcNAcylation, AMPK, OGT, novel O-GlcNAcylation site
Abstract

Background
O-GlcNAcylation, an energy-sensitive post-translational modification, plays a major role in endothelial nitric oxide synthase (eNOS) activity regulation. However, the effect of hypoglycemia on eNOS O-GlcNAcylation and whether eNOS exists the novel O-GlcNAcylation sites under hypoglycemia is unknown. Hence, we endeavored to determine the effects of hypoglycemia on eNOS O-GlcNAcylation and the novel O-GlcNAcylation sites of eNOS.

Method
Bovine aortic endothelial cells (BAECs) and Sprague-Dawley rats were treated by hypoglycemia, and using immunoblotting to measure their eNOS O-GlcNAcylation. eNOS and transfected eNOS were purified by pull-down assay and immunoprecipitation respectively. Novel O-GlcNAcylation sites of eNOS were predicted by HPLC-MS and MS/MS Ion, and determined by immunoblotting. eNOS activity were detected by Elisa and isotope labelling method.

Results
In BAECs and rats` thoracic aorta, hypoglycemia-associated activation of eNOS was accompanied by an increase in O-GlcNAcylation and had no effect on O-linked serine phosphorylation at residue 1179/1177. Changes in this post-translational modification were associated with increased O-GlcNAc transferase (OGT) activity, and were reversed by AMPK knockdown. Immunoblot analysis of cells expressing His-tagged wild-type human eNOS and human eNOS carrying a mutation at the Ser1177 phosphorylation site confirmed the increase in O-GlcNAcylation in response to hypoglycemia. The observed increase in O-GlcNAcylation indicated that eNOS contains novel O-GlcNAcylation sites that are activated by hypoglycemia. Immunoblot analysis of cells expressing His-tagged human eNOS carrying a mutation at Ser738 and Ser867 confirmed the increase in O-GlcNAcylation in response to hypoglycemia. Contrastingly, in His-tagged human eNOS carrying a mutation at Thr866, O-GlcNAcylation was unaffected by hypoglycemia. Differences among culture conditions were identified using two-way analysis of variance (ANOVA), one-way ANOVA, or unpaired Student’s t-test.

Conclusions
Hypoglycemia increases eNOS O-GlcNAcylation and activity, potentially via AMPK-OGT pathway, thereby showing the Thr866 as a novel O-GlcNAcylation site involved in hypoglycemia-mediated eNOS activation.

**Background**

eNOS plays an important role in regulating the cardiovascular system. eNOS also functions in the synthesis of nitric oxide (NO), an endogenous vasodilator, thus playing a key role in vasodilatation (1). Endothelial NO also contributes to vessel homeostasis by regulating cell growth, platelet aggregation, and the binding of leukocytes to endothelial cells (2–4). Endothelium-dependent relaxation is dysregulated in both micro-circulation and macro-circulation during acute hypoglycemia in both normal subjects and patients with diabetes, suggesting that eNOS activity may be affected by hypoglycemia (5, 6). eNOS activity is subject to several overlapping modes of post-translation modifications; phosphorylation and O-GlcNAcylation are two major post-translation modifications of eNOS that provide mechanisms for the dynamic stimulation and inhibition of enzymatic activity (7). As a nutrient-sensitive post-translational modification, O-GlcNAcylation controls the intensity of signals travelling through different pathways according to the nutritional status of the cell (8).

However, the major pathways controlling the O-GlcNAcylation of eNOS in response to hypoglycemia, as well as the underlying mechanisms by which hypoglycemia changes eNOS activity, are unknown. One major biochemical pathway controlling hypoglycemia-induced O-GlcNAcylation have recently been shown: AMPK activation induced by hypoglycemia (9). Hypoglycemia-induced activation of OGT via AMPK, and the activation of the OGT by this mechanism, were found to increase protein O-GlcNAcylation (9, 10). We therefore hypothesized that hypoglycemia may affect eNOS activity via AMPK-induced OGT activation, resulting in O-GlcNAcylation and changes in NO production.

O-GlcNAcylation often competes with phosphorylation in the regulatory pathways of the cell, competition prediction server has identified several Ser and Thr residues in eNOS that may be targeted by phosphorylation or O-GlcNAcylation (11, 12). In eNOS, hyperglycemia increases O-GlcNAcylation and reciprocally decreases phosphorylation at Ser-1177 (12, 13). Previous investigations have mainly focused on how hyperglycemia induces an imbalance of competitive
modification between O-GlcNAcylation and phosphorylation in eNOS; however, few investigations
have analyzed the effects of hypoglycemia on this competitive modification (14). The objectives of
the present work were to elucidate the glycosylation of eNOS sites in response to hypoglycemia and
to identify potential O-GlcNAcylation sites. To identify potential O-GlcNAcylation sites, the
glycosylated amino acid residues were identified by the fractionation of chymotryptic peptides using
high-pressure liquid chromatography-mass spectrometry (HPLC-MS).

Methods

Plasmid Construction

eNOS-wild-type (WT)—The cDNA sequence of human eNOS (kindly provided by Dr. Yong Xia) was
subcloned into pCDN3.1 (His-tagged). eNOS-S1177A, eNOS-T866A, eNOS-S867A and eNOS-S738A are
point mutant of eNOS-WT were constructed by site-directed mutagenesis (Ser1177, Thr866, Ser867,
Ser738 mutated to Ala). All mutations were performed by TransGen (TransGen Biotech, Beijing,
China) and were confirmed by direct sequencing.

Cell Culture, Transfection, and Hypoglycemia Induction

Bovine aortic endothelial cells (BAECs, passages 6–10) and human embryonic kidney (HEK293) cells
were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) FBS (Invitrogen)
and 1 % (v/v) penicillin/streptomycin (PS) (Beyotime Biotechnology, JiangSu, China) in a humidified
incubator at 37 °C with 5% CO₂. For cell transfection, BAECs grown in 100-mm dishes were
transfected with plasmids encoding eNOS-WT and eNOS mutants using Lipofectamine 3000
(Invitrogen) following the manufacturer’s instructions and then analyzed 48 h after transfection.
HEK293 cells in 6-well cell culture plates were transfected with plasmids encoding eNOS-WT or the
eNOS mutants using Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions and
then analyzed 24 h after transfection. To induce hypoglycemia (LG), BAECs and HEK293 cells were
cultured with medium containing 1 mmol/L glucose.

AMPKα1 Gene Silencing in BAECs

The sense (5’-GAUCCAUCAUAUGCUAAAdTdT-3’) and antisense (3’-UGAGCUAUAUGAUGGACdTdT-5’)
Small interfering RNA (siRNA) strands of AMPKα1 were purchased from Biomic (Nanjing, China).
siRNA oligonucleotides (75 nM) were delivered into cells using Opti-MEM (Invitrogen) and Lipofectamine 2000 according to the manufacturer's protocol. After transfection for 48 h, cells were subjected to further experiments.

**Preparation of Protein Samples from Cells**

After culturing, cells were harvested by scraping. Harvested cells were washed three times with ice-cold PBS, resuspended in 100 μl lysis buffer (Beyotime) containing protease inhibitor cocktail (Beyotime) and PUGNAC (Sigma Aldrich, St. Louis, MO, USA) in a clean Eppendorf tube, and kept on ice for 1 h. The homogenate was then centrifuged at 13800 × g and 4 °C for 15 min and the supernatant were recovered. The concentration of supernatant was determined by the Bradford protein assay.

**Preparation of Protein Samples from Rat Aortae**

Male and Female Sprague-Dawley rats approximately 6 to 8 weeks of age and 180 to 220 g weight were purchased from Experimental Animal Center of Chongqing Medical University. All animal procedures were carried out according to the guidelines of the China Animal Protection Law and were approved of by the Institutional Ethics Committee of Chongqing Medical University [Permit No. SCXK (Chongqing) 2007–0001] and the State Science and Technology Commission of China. Animals were housed individually and maintained on a 12 h light/12 h dark schedule at 22–23 °C with ad libitum access to food and water.

After overnight fasted, rats (200–250 g) were randomly divided into 4 groups (5 rats in each group): control group, hypoglycemia for 3, 6 and 9 h group. In hypoglycemia groups, rats were treated by glargine insulin (Lantus-Solostar, Paris, France) with subcutaneous injection (200 g /U). In control group, rats were treated by PBS with subcutaneous injection (200 g /1 ml). Blood glucose was monitored every 30 min from 0 to 9 hours after insulin injection via tail prick, hypoglycemia was considered when glycemic < 3 mmol/l (14, 15). Rats were anesthetized by 2 % sodium pentobarbital solution with subcutaneous injection (0.002 ml /g). The thoracic aorta was quickly removed, and washed by ice cold PBS. After washing with ice-cold PBS, rat thoracic aortae were cut into pieces. Tissues were resuspended in lysis buffer containing protease inhibitor cocktail and PUGNAC in a clean
Eppendorf tube. Tubes were placed on a cracker and the tissues were homogenized for 70 min at 4 °C. Lysate supernatants were collected by centrifugation at 13800 × g for 15 min at 4 °C. The concentration of supernatant was determined by the Bradford protein assay.

**Immunoprecipitation**

For immunoprecipitation, aliquots of cell homogenates were incubated with polyclonal antibodies targeting OGT (4 μg/ml) (Abcam, Cambridge, UK) overnight at 4 °C. Protein G-Sepharose beads (GE Healthcare, Chicago, IL, USA) were added to the supernatant and incubated for 3 h. The beads were washed thoroughly with lysis buffer and then eluted by boiling for 3 min in SDS-PAGE sample buffer (Beyotime).

**eNOS Pull-down Assay**

In BAEC and rat thoracic aorta, eNOS was extracted from the lysate by affinity precipitation using 2′,5′-ADP Sepharose beads (GE Healthcare). Cell/tissue lysates were and mixed with prepared 2′,5′-ADP Sepharose resins (50% slurry) at 4 °C for 2 h with gentle shaking. The mixture was then centrifuged at 13800 × g for 1 min. The supernatant was discarded, and the resins were washed with washing buffer (PBS supplemented with 500 mM NaCl) three times. Bound proteins were eluted by boiling the resins in 50 μl SDS-PAGE sample buffer for 10 min. For transfected cells, eNOS was extracted by affinity precipitation after transfection using the His-tag protein purification Kit (Beyotime) per the manufacturer’s protocol.

**Immunoblotting**

For western blotting, proteins were fractionated by SDS-PAGE and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). After blocking for 1.5 h in blocking buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5% skim milk powder, 0.1% (v/v) Tween-20) at room temperature, the membranes were reacted with the appropriate primary antibodies (primary antibodies 1:2000; diluted in blocking buffer) at 4 °C overnight. Thereafter, membranes were thoroughly washed three times with TBST (20 mM Tris-Cl (pH 7.5), 150 mM NaCl, 0.1% (v/v) Tween-20) for 10 min per wash. Membranes were then incubated in 1:5000 diluted secondary antibody for 1.5 h, thoroughly washed three times (10 min per wash) with TBST, and finally detected by chemiluminescence (Advansta Inc., San Jose, CA, USA).
Primary antibodies targeting phospho-eNOS Ser1177, phospho-eNOS Ser633, phospho-eNOS Thr495, and eNOS were purchased from Cell Signaling Technology (Danvers, MA, USA); O-GlcNAc antibody (RL2) was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Antibodies targeting O-GlcNAcase (OGA), Threonine, phospho-AMPK Thr172, and anti-AMPKα1 were purchased from Abcam (Cambridge, UK); β-actin antibody was purchased from Proteintech (Rosemont, IL, USA). Goat anti-mouse IgG and Goat anti-rabbit IgG were purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and Proteintech, respectively.

**Preparation of eNOS for HPLC-MS**

eNOS was extracted by affinity precipitation from eNOS-WT-transfected HEK293 cells using the His-tag protein purification Kit. Affinity-precipitated eNOS was fractionated by SDS-PAGE, and the gel was stained with Coomassie brilliant blue. Stained eNOS was excised from the gel and stored in a clean Eppendorf tube after the excised gel was proven to contain eNOS by immunoblotting using the Micro Protein PAGE Recovery Kit (Sangon Biotechnology, Shanghai, China). Gels in the Eppendorf tubes were decolorized and swelled. After de-coloration and swelling, absolute acetonitrile was added to shrink and solidify the gel. At last, the acetonitrile was then absorbed and the gel was heat-dried. Dithiothreitol (DTT) solution were added to the tubes and mixed thoroughly, then incubated at 56 °C for 1 h; after incubation, the solution was discarded and the sample was heat-dried. Indole-3-acetic acid (IAA) solution was added, mixed well, and the mixture was incubated at room temperature for 30 min; thereafter, the solution was discarded and DTT was added. The mixture was incubated at room temperature for 15 min for neutralize any remaining IAA; the solution was then discarded and the sample was heat-dried. Chymotrypsin was added to the sample at an enzyme/protein ratio of 1:20 in a reaction system containing 200 μl 50 mmol/L ammonium bicarbonate solution, and incubated at 37 °C for 14 h. After the enzymatic digestion was completed, the enzymatic digestion solution was successively added with 1% TFA solution, 60% acetonitrile solution, 0.1% TFA solution, and absolute acetonitrile solution. The reaction was conducted at 37 °C for 1 h respectively, and the reaction solution was combined.

**HPLC-MS for Enrichment of eNOS O-Glycosylation**
Digested samples were dissolved in A solution (deionized H₂O containing 0.1% formic acid) and centrifuged at 1000 × g for 5 min; the supernatants were then tested using the Thermo Orbitrap Lumos HPLC-MS system with a data collection time of 120 min, spray voltage of 2.20 kV, capillary temperature of 320 °C, collision energy of 50%, first-level mass range of collection of 300-1800 m/z, and second-level scanning range of 100-1400 m/z. Data from HPLC-MS for the enrichment of eNOS O-glycosylation were provided by the Beijing Proteome Research Center Tandem Mass Spectrometry (MS/MS) laboratory (China).

**Measurement of NO**

The concentration of NO released from BAECs in culture medium was measured in terms of the concentration of nitrate and nitrite using a modified Griess reaction method with the Total Nitric Oxide Assay Kit (Beyotime). Aorta blood samples from normal and hypoglycemic rats were collected using vacuum hemostix. Plasma was stored at -80 °C until assay. NO concentrations were determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) per the manufacturer’s protocol.

**eNOS Activity Assay**

eNOS activity was measured from the conversion rate of L-[14C] Arginine to L-[14C] Citrulline in cells. The conversion was monitored at a total volume of 300 ul buffer containing 50 mM Tris-HCl, pH 7.4, 5 μM L-[14C] arginine (Moravek, Brea, CA, USA), 45 μM L-arginine, 0.5 mM NADPH, 10 μM BH4, 10 μg/ml calmodulin, and 10 nM eNOS. The reactions were initiated by adding L-[14C] arginine and terminated by stop buffer (20 mM HEPES, 2 mM EDTA) after 1 h incubation at 37 °C. L-[14C] Citrulline was separated by passing the reaction mixture through a Dowex AG 50W-X8 (Na⁺ form) (Sigma) cation exchange columns and quantitated by liquid scintillation counting. N(gamma)-nitro-L-arginine methyl ester (L-NAME; 5 mM) inhibitory activity was analyzed to determine the concentration of L-[14C] citrulline converted by eNOS.

**Statistical analysis**

All data are presented as the mean ± standard error of the mean (SEM). Statistical analysis was
performed using SPSS by two-way analysis of variance (ANOVA), one-way ANOVA, or unpaired Student’s t-test. A value of $P < 0.05$ was considered statistically significant. Data analysis was performed using SPSS version 25 (SPSS Inc/IBM, Chicago, Ill, USA).

**Results**

**Hypoglycemia increases eNOS O-GlcNAcylation and has no effect on O-linked phosphoserine (Ser1179)**

To confirm that hypoglycemia affects eNOS O-GlcNAcylation, western blotting was performed to detect O-GlcNAcylation and phospho-eNOS (Ser1179) under glucose deprivation. As demonstrated in Fig. 1A, the ratio of eNOS O-GlcNAcylation to eNOS increased by 3.5-fold over 10 h of glucose deprivation, whereas phospho-eNOS (Ser1179) was not affected, suggesting that glucose deprivation only increased eNOS O-GlcNAcylation. To determine the concentration of glucose with the same effect on eNOS as glucose deprivation, western blotting was performed to detect O-GlcNAcylation and phospho-eNOS (Ser1179) under different low-glucose concentrations. As demonstrated in Fig. 1B, the ratio of eNOS O-GlcNAcylation to eNOS increased by 2.2-fold after 6 h of graded glucose concentration reduction from 5.5 to 1 mM; this ratio continued to increase from 2.2 to 2.5-fold following a graded reduction from 1 to 0 mM. In contrast, phospho-eNOS (Ser1179) was not changed, suggesting that 1 mM glucose had the same effect on eNOS O-GlcNAcylation as glucose deprivation. As demonstrated in Fig. 1C, 1 mM glucose had the same effect as glucose deprivation. These data strongly suggest that hypoglycemia only increases eNOS O-GlcNAcylation and has no effect on phospho-eNOS (Ser1179).

**Hypoglycemia increases eNOS O-GlcNAcylation through OGT up-regulation and AMPK activation**

Previous investigations demonstrated that OGT and OGA are two enzymes that regulate O-GlcNAcylation cycling (16). In order to identify which enzyme regulates eNOS O-GlcNAcylation under hypoglycemia, affinity precipitation of eNOS followed by western blotting with antibodies targeting OGT and OGA were performed, as shown in Fig. 2A. It was found that hypoglycemia increased OGT by 50%, while reciprocal OGA expression was unchanged. It was observed that Thr phosphorylation could
activate OGT (17); therefore, to confirm that hypoglycemia activates OGT via phosphorylation, the immunoprecipitation of OGT followed by western blotting with antibodies targeting phospho-Thr were performed. As demonstrated in Fig. 2B, the ratio of phospho-Thr OGT to OGT increased by 50% after incubation for 6 h under hypoglycemic conditions, suggesting that hypoglycemia increased OGT phosphorylation at its Thr site. These data suggest that hypoglycemia not only increases eNOS O-GlcNAcylation by inducing the binding of OGT to eNOS, but also activates OGT through its phosphorylation. As a cell energy sensor, AMPK can be activated by a decreased extracellular ATP/ADP ratio and plays a role in protein O-GlcNAcylation (9, 17). To confirm that AMPK played a role in eNOS O-GlcNAcylation, western blotting to detect O-GlcNAcylation, eNOS, P-AMPK Thr172, and AMPK was performed. As demonstrated in Fig. 2C, the ratio of eNOS O-GlcNAcylation to eNOS increased by 2.5-fold, while the ratio of P-AMPK to AMPK was also increased by 2-fold, after 6 h incubation under hypoglycemic conditions. AMPKα1 knockdown was shown to reverse these effects of eNOS O-GlcNAcylation and AMPK phosphorylation. These data strongly suggest that hypoglycemia increases eNOS O-GlcNAcylation in an AMPK-dependent manner.

**Hypoglycemia increases eNOS O-GlcNAcylation in rat aortae**

In the above results, we identified that hypoglycemia increases eNOS O-GlcNAcylation in vitro. To confirm that hypoglycemia also increases eNOS O-GlcNAcylation in vivo, we measured the blood glucose concentration of rats after insulin injection. As demonstrated in Fig. 3A, rats subcutaneously injected with insulin showed significantly lower rates of glycemia at 3 h after insulin injection. Western blotting to detect O-GlcNAcylated and phospho-eNOS (Ser1177) under hypoglycemia were performed. As demonstrated in Fig. 3B, the ratio of eNOS O-GlcNAcylation to eNOS increased by 2.5-fold over 9 h following hypoglycemia exposure, whereas phospho-eNOS (Ser1177) was not changed. These data strongly suggest that hypoglycemia only increases eNOS O-GlcNAcylation and has no effect on phospho-eNOS (Ser1177) both in vitro and in vivo.

**Hypoglycemia increases O-GlcNAcylation at the mutated eNOS Akt phosphorylation site**

To confirm whether eNOS has a novel O-GlcNAcylation sites, the effects of hypoglycemia on eNOS O-GlcNAcylation and O-linked phosphoserine at this residue were evaluated using WT-eNOS and
S1177A-eNOS. As demonstrated in Fig. 4A, hypoglycemia increased the O-GlcNAcylation of WT-eNOS and had no effect on phospho-eNOS (Ser1177). As demonstrated in Fig. 4B, S1177A-eNOS stills exists O-GlcNAcylation. As demonstrated in Fig. 4C, O-GlcNAcylation was increased in S1177A-eNOS in response to hypoglycemia. As demonstrated in Fig. 4D, BAECs transfected with WT-eNOS and S1177-eNOS both showed an increase in O-GlcNAcylation in response to hypoglycemia. These data suggest that eNOS may have a novel O-GlcNAcylation sites that is activated in response to hypoglycemia.

**HPLC-MS and MS/MS Ion search for the hypoglycemia-dependent O-GlcNAcylation sites of eNOS**

To determine whether eNOS has novel O-GlcNAcylation sites, purified eNOS samples (excised gel) were analyzed by HPLC-MS, as demonstrated in Fig. 5A. To confirm that the analysis samples for HPLC-MS contained eNOS, proteins were recovered from the gels using the Micro Protein PAGE Recovery Kit. Western blotting against eNOS was then performed, as shown in in Fig. 5A (inset). To determine whether the novel O-GlcNAcylation sites obtained by MS/MS Ion Search (Fig. 5B and 5C (left panel)) were in fact major hypoglycemia-dependent O-GlcNAcylation sites, western blotting to detect O-GlcNAcylation under hypoglycemia was performed. As demonstrated in Fig. 5B (right panel), HEK293 cells transfected with S867A-eNOS showed an increase in O-GlcNAcylation in response to hypoglycemia. As demonstrated in Fig. 5C (right panel), HEK293 cells transfected with T866A-eNOS showed no changes in O-GlcNAcylation in response to hypoglycemia. Finally, as demonstrated in Fig. 5D, BAECs transfected with T866A-eNOS showed no changes in O-linked GlcNAc in response to hypoglycemia. These data strongly suggest that Thr866 is a novel O-linked GlcNAc site under hypoglycemia.

**Hypoglycemia increases eNOS activity**

To confirm that increased O-GlcNAcylation would affect the synthesis of NO by eNOS under hypoglycemia, we measured changes in the production of NO in cell culture medium under hypoglycemic conditions. As demonstrated in Fig. 6A, the production of NO was increased by 3-fold after incubation for 10 h under hypoglycemic conditions. Moreover, to confirm that increased O-GlcNAcylation also affected eNOS function *in vivo*, we measured changes in the production of NO in
rat aorta plasma. As demonstrated in Fig. 6B, the production of NO was increased by 40% at 6 h after hypoglycemia induction. These data strongly suggest that hypoglycemia increases the NO synthesis function of eNOS both in vitro and in vivo. Above, we showed that eNOS has a novel hypoglycemia-dependent O-GlcNAcylation site. To confirm that the novel O-GlcNAcylation site would affect NO synthesis by eNOS, we analyzed the changes in eNOS activity in WT-eNOS and T866A-eNOS in transfected HEK293 cells. As demonstrated in Fig. 6C, eNOS-catalyzed L-[14C] citrulline formation by WT-eNOS was increased by 10-fold compared to that in T866A-eNOS. These data show that eNOS has a novel hypoglycemia-dependent O-GlcNAcylation site, and that this site was located at Thr866.

Discussion
In this report, we have shown that hypoglycemia increases eNOS activity in cultured BAECs by increasing OGT phosphorylation and attachment to eNOS via AMPK activation, which increases eNOS modification by GlcNAc. When incubated with 1 mM glucose, AMPK knockdown by siRNA reversed these modifications, as expected (9, 17), suggesting that hypoglycemia-induced increases in O-GlcNAcylation are required for energy sensors to sense a decrease in the ATP/ADP ratio. These modifications appear to occur specifically at the O-GlcNAcylation site. Residues such as Ser1177 are modified by GlcNAc (12, 13); however, hypoglycemia did not decrease the rate of modification at these sites. In aortae from hypoglycemic rats, changes in both the covalent modification of eNOS and eNOS activity resembled those observed in BAECs cultured in 1 mM glucose. To our knowledge, this is the first report showing eNOS modification by GlcNAc under hypoglycemia, and the first to reveal its underlying mechanisms. Additionally, these findings are the first example of functional alterations in a cytoplasmic enzyme induced by these modifications under hypoglycemia. There exists previous studies demonstrated that cell proteins could dynamically modified by O-GlcNAc moieties due to hypoglycemia (9, 10, 18, 19). Although these observations were not made in endothelial cells, but rather focused on modifications in whole cell proteins, the same mechanism most likely explains the increase in eNOS O-GlcNAcylation in hypoglycemia.

These data are somewhat consistent with previous observations indicating that glucose deprivation increases protein O-GlcNAcylation through the up-regulation of OGT (10, 17, 19). However, detecting
O-GlcNAcylation at the whole-cell protein level may have missed several crucial biological phenomena in response to hypoglycemia. Different post-translational modifications induce different responses to hypoglycemia, and competition has been observed among those modifications (5, 13). Because we investigated O-GlcNAcylation in eNOS isolated by affinity purification, the influence of the O-GlcNAcylation of other proteins in response to hypoglycemia was not existed. Additionally, because we identified a competitive modification site of O-GlcNAcylation by immunoblotting, these findings may improve our understanding of how hypoglycemia regulates eNOS activity through post-translational modifications. In addition to the underlying mechanism of hyperglycemia-induced eNOS O-GlcNAcylation, hypoglycemia also increased OGT activity by inducing phosphorylation and attachment to eNOS in an AMPK-dependent manner. This indicates that hypoglycemia increases eNOS O-GlcNAcylation through another signal pathway that independent of increased HBP flux and appears distinct from previously reported hyperglycemia-induced O-GlcNAcylation (20). In the cardiovascular system of patients with diabetes, several pathophysiological changes occur to prevent the inhibition of eNOS activity by hyperglycemia (21). Epidemiological studies have established an association between inflammatory biomarkers and the occurrence of diabetes and related complications (22). Diabetes increases the serum levels of cytokines, inflammatory factors, and induces oxidative stress; these responses also inhibit eNOS activity by decreasing Ser1177 phosphorylation (23). Hence, we propose that even in a pre-diabetic state without macro- or micro-vascular complications, the homeostasis of endothelial cells and eNOS activity is impaired by dysregulated metabolism, increased oxidative stress, and the expression of inflammatory factors. As a nutrient-sensitive modification site, the increased O-GlcNAcylation of eNOS may be initially triggered by metabolic dysregulation and function in the metabolic memory of endothelial cells (12, 13, 20). Additionally, changes in phosphorylation allow rapid integrative responses to stimuli; thus, Ser1177 phosphorylation may have been decreased during early pre-diabetic stages. Moreover, hypoglycemia increased vessel blood flow in normal rats, but decreased endothelium-dependent relaxation in diabetes patients (5, 6). To some extent, these contradictory results which occurred in hypoglycemia rats may also support our findings.
Previous investigations have shown the significance of hyperglycemia-induced O-GlcNAcylation of eNOS in the inhibition of its enzyme activity (12, 13, 20) by increasing O-GlcNAcylation in eNOS, accompanied by a reciprocal decrease in O-linked serine phosphorylation at Ser1177 (12, 13). However, in this study, this reciprocal activity was not observed when hypoglycemia induced an increase in eNOS O-GlcNAcylation both in vitro and in vivo. Because we determined that eNOS O-GlcNAcylation site under hypoglycemia condition is different from hyperglycemia. We demonstrated that our S1177A-eNOS mutant still underwent O-GlcNAcylation, and that hypoglycemia induced this modification. Based on these phenomena, we propose that eNOS contains a potential O-GlcNAcylation site that is modified in response to hypoglycemia. Through HPLC-MS, we identified novel hypoglycemia-dependent O-GlcNAcylation sites in eNOS. We confirmed the identities of the novel O-GlcNAcylation sites by transfecting and expressing site-specific mutant eNOS proteins based on the sites predicted by MS. When transfected HEK293 cells and BAECs were incubated in hypoglycemic conditions, the O-GlcNAcylation of T866A-eNOS was not increased, showing that Thr866 is a novel O-GlcNAcylation site. Moreover, compared to that of T866A-eNOS, the activity of WT-eNOS was increased 8- to 10-fold. These data suggest that the regulation of eNOS activity under hypoglycemia occurs in part through the regulation of O-GlcNAcylation. This is the first study to construct functional alterations in eNOS induced by novel O-GlcNAcylation site modification. These data are partially consistent with previous results showing that hypoglycemia increases eNOS activity (5). However, whether hypoglycemia increases NO production and blood flow in the hypothalamic-hypophyseal portal system by increasing Ser1177 eNOS phosphorylation is still controversial (5, 24).

Based on our findings, we suspect that this occurs through increased O-GlcNAcylation of eNOS Thr866. Furthermore, we suspect that this modification may activate enzyme activity by increasing the Km of the enzyme. In our experiment, we first purified eNOS from cultured cells by affinity precipitation to ensure that NO synthesized by cell components or tissues other than eNOS was eliminated. Moreover, we excluded other positive regulatory site of eNOS to ensure that eNOS activity was only related to its O-GlcNAcylation. It is known that physiological concentrations of insulin may increase eNOS activity by increasing phosphorylation at Ser1177 (25). This effect of insulin was
eliminated because cells were treated in “pure” hypoglycemic conditions without any eNOS activators. Hence, the only factor affecting post-translational modifications of eNOS was a decreased glucose concentration. This novel O-GlcNAcylation site may be a specific “metabolic memory point” for eNOS in response to hypoglycemia. Furthermore, the novel modification reported here may provide a basis for the development of new energy-sensitive targets to prevent obesity-induced angiosclerosis. Such a target may help to prevent the development and progression of diabetes-associated severe vasospasm.

There were several limitations to this study. Acetylation is another nutrient-sensitive post-translational modification of eNOS, and its effect on eNOS activity in hypoglycemic conditions must be clarified in subsequent studies. In the future, the effect of the T866A eNOS mutant on endothelial cell signaling transduction and its protein-protein interaction should be investigated.

**Conclusions**

Our study demonstrates that hypoglycemia increases eNOS O-GlcNAcylation *in vivo* and *in vitro*. Hypoglycemia induced O-GlcNAcylation activation, possibly via AMPK-OGT pathway, hence pointing to the Thr866 as a novel O-GlcNAcylation site involved in hypoglycemia-mediated NO synthesis.

**Abbreviations**

eNOS  
endothelial nitric oxide synthase  
BAECs  
bovine aortic endothelial cells  
OGT  
O-GlcNAc transferase  
AMPK  
AMP kinase  
NO  
nitric oxide  
HPLC-MS  
high-pressure liquid chromatography-mass spectrometry  
SiRNA  
Small interfering RNA (siRNA)

**Declarations**
Ethics approval and consent to participate

All animal procedures were carried out according to the guidelines of the China Animal Protection Law and were approved of by the Institutional Ethics Committee of Chongqing Medical University [Permit No. SCXK (Chongqing) 2007–0001] and the State Science and Technology Commission of China.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by grants from the National Basic Research program of China (No.2014CB542402) and the National Nature Science Foundation of China (No.81270210).

Authors’ contributions

An He, analyzed, collected the data and wrote the manuscript. Suxin Luo and Piqiang Zhong ensure the English language is of sufficient quality to be understood and fund the study. An He, Yang Long and Shupeng Hu isolated and purified the BAECs from bovine thoracic aorta. Yong Xia conceived, designed and fund the study, and conducted the experiments. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Erkens R, Suvorava T, Kramer CM, Diederich LD, Kelm M, Cortese-Krott MM.. (2017). Modulation of local and systemic heterocellular communication by mechanical forces:
a role of endothelial nitric oxide synthase. *Antioxidants & Redox Signaling*, ars.2016.6904.

2. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. Journal of Clinical Investigation. 1997;99(2):278-87.

3. Kader KN, Akella R, Ziats NP, Lakey LA, Harasaki H, Ranieri JP, et al. Enos-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitro. Tissue Eng. 2000;6(3):241.

4. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res. 1993;27(7):1380.

5. Cabou C, Cani PD, Campistron G, Knauf C, Mathieu C, Sartori C, et al. Central insulin regulates heart rate and arterial blood flow: an endothelial nitric oxide synthase dependent mechanism altered during diabetes. Diabetes. 2007;56(12):2872-7.

6. Ceriello A, Novials A, Ortega E, Sala LL, Pujadas G, Testa R, et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012;61(11):2993-7.

7. Dirsch VM, Heiss EH.. (2014). Regulation of enos enzyme activity by posttranslational modification. current pharmaceutical design, 20(22).

8. Issad T, Masson E, Pagesy P. O-glcnac modification, insulin signaling and diabetic complications. Diabetes Metabolism. 2010;36(6-part-P1):0-435.

9. Cheung WD, Hart GW. Amp-activated protein kinase and p38 mapk activate o-glcnacylation of neuronal proteins during glucose deprivation. J Biol Chem.
10. Taylor RP, Parker GJ, Hazel MW, Soesanto Y, Fuller W, Yazzie MJ, et al. Glucose deprivation stimulates o-glcnac modification of proteins through up-regulation of o-linked n-acetylglucosaminyltransferase. J Biol Chem. 2008;283(10):6050–7.

11. Julenius K, Mølgaard A, Gupta R, Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type o-glycosylation sites. Glycobiology. 2005;15(2):153–64.

12. Musicki B, Kramer MF, Becker RE, Burnett AL.. (2005). Inactivation of phosphorylated endothelial nitric oxide synthase (ser-1177) by o-glcnac in diabetes-associated erectile dysfunction. Proceedings of the National Academy of Sciences, 102(33), 11870–11875.

13. Liang DX, Diane E, Stefanie D, Qida J, Chengyu S, Michael B. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the akt site. Journal of Clinical Investigation. 2001;108(9):1341–8.

14. Moore H, Craft TKS, Grimaldi LM, Babic B, Brunelli SA, Vannucci SJ. Moderate recurrent hypoglycemia during early development leads to persistent changes in affective behavior in the rat. Brain Behav Immun. 2010;24(5):0–849.

15. None. Glucose concentrations of less than 3.0?mmol/l (54?mg/dl) should be reported in clinical trials: a joint position statement of the american diabetes association and the european association for the study of diabetes. Diabetologia. 2017;60(1):3–6.

16. Aquino-Gil M, Pierce A, Perez-Cervera Y, Zenteno E, Lefebvre T. Ogt: a short overview of an enzyme standing out from usual glycosyltransferases. Biochem Soc Trans. 2017;45(2):365–70.

17. Bullen JW, Balsbaugh JL, Chanda D, Shabanowitz J, Hunt DF, Neumann D, et al. Cross-talk between two essential nutrient-sensitive enzymes: o-glcnac transferase (ogt)
and amp-activated protein kinase (ampk). J Biol Chem. 2014;289(15):10592–606.

18. Kang JG, Park SY, Ji S, Jang I, Park S, Kim HS, et al. O-glcnac protein modification in cancer cells increases in response to glucose deprivation through glycogen degradation. J Biol Chem. 2009;284(50):34777–84.

19. Taylor RP, Geisler TS, Chambers JH, Mcclain DA. Up-regulation of o-glcnac transferase with glucose deprivation in hepg2 cells is mediated by decreased hexosamine pathway flux. J Biol Chem. 2009;284(6):3425–32.

20. Issad T, Masson E, Pagesy P. O-glcnac modification, insulin signaling and diabetic complications. Diabetes Metabolism. 2010;36(1):6-part-P. 0–435.

21. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. Journal of Diabetes. 2017;9(5):434–49.

22. Lontchiyimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr DiabRep. 2013;13(3):435–44.

23. Musicki B, Burnett AL. Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res. 2007;19(2):129–38.

24. Fioramonti X, Marsollier N, Song Z, Fakira KA, Patel RM, Brown S, et al. Ventromedial hypothalamic nitric oxide production is necessary for hypoglycemia detection and counterregulation. Diabetes. 2010;59(2):519–28.

25. Kuboki K, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo. Circulation. 2000;101:676–81.

Figures
Figure 1
Figure 1

Effect of hypoglycemia on bovine aortic endothelial cell (BAEC) endothelial nitric oxide synthase (eNOS) O-GlcNAcylation. A: Left panel: Representative western blot of BAEC eNOS O-GlcNAcylation and phospho-eNOS (Ser1177) from control or glucose deprivation-treated cells (n = 3) over 10 h. Right panel: quantification of the ratio between O-GlcNAcylation, phosphorylated eNOS (P-eNOS), and eNOS. B: Left panel: representative western blot of BAEC O-GlcNAcylation, P-eNOS, and eNOS in response to a decrease in extracellular glucose from 5.5 to 0 mM (n = 3) over 6 h. Right panel: quantification of the ratio between O-GlcNAcylation, P-eNOS, and eNOS. C: Left panel: representative western blot of BAEC eNOS O-GlcNAcylation and phospho-eNOS (Ser1177) from control or 1 mM glucose-treated cells (n = 3) over 10 h. Right panel: quantification of the ratio between O-GlcNAcylation, P-eNOS, and eNOS. Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. * P < 0.05 vs. control. Squares = O-GlcNAc; circles = P-eNOS 1179.
Figure 1
Effect of hypoglycemia on bovine aortic endothelial cell (BAEC) endothelial nitric oxide synthase (eNOS) O-GlcNAcylation. A: Left panel: Representative western blot of BAEC eNOS O-GlcNAcylation and phospho-eNOS (Ser1177) from control or glucose deprivation-treated cells (n = 3) over 10 h. Right panel: quantification of the ratio between O-GlcNAcylation, phosphorylated eNOS (P-eNOS), and eNOS. B: Left panel: representative western blot of BAEC O-GlcNAcylation, P-eNOS, and eNOS in response to a decrease in extracellular glucose from 5.5 to 0 mM (n = 3) over 6 h. Right panel: quantification of the ratio between O-GlcNAcylation, P-eNOS, and eNOS. C: Left panel: representative western blot of BAEC eNOS O-GlcNAcylation and phospho-eNOS (Ser1177) from control or 1 mM glucose-treated cells (n = 3) over 10 h. Right panel: quantification of the ratio between O-GlcNAcylation, P-eNOS, and eNOS. Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. * P < 0.05 vs. control. Squares = O-GlcNAc; circles = P-eNOS 1179.
Figure 2
Increased O-GlcNAcylation stimulated by hypoglycemia is caused by AMP kinase (AMPK)-dependent O-GlcNAc transferase (OGT) activation. A: Left panel: representative western blot of OGT and O-GlcNAcase (OGA) from control or hypoglycemia (LG)-treated bovine aortic endothelial cells (BAECs) (n = 3) incubated for 6 h. Right panel: quantification of the ratio between OGT and OGA. B: Left panel: representative western blot of phospho-threonine OGT and OGT from control or LG-treated BAECs (n = 3) incubated for 6 h. Right panel: quantification of the ratio between phospho-threonine OGT and OGT. C: Left panel: representative western blot of AMPK, P-AMPK, eNOS O-GlcNAcylation, and eNOS from control or hypoglycemia-treated BAECs or AMPKα1-knockdown BAECs (n = 3) incubated for 6 h. Right panel: quantification of the ratio of AMPK, P-AMPK, eNOS O-GlcNAcylation, and eNOS. Data are shown as the mean ± SEM and represented as a percentage of control, where the control group was considered to be 100%. ** P < 0.01 vs. control. White = P-AMPK; black = O-GlcNAc.
Figure 2
Increased O-GlcNAcylation stimulated by hypoglycemia is caused by AMP kinase (AMPK)-dependent O-GlcNAc transferase (OGT) activation. A: Left panel: representative western blot of OGT and O-GlcNAcase (OGA) from control or hypoglycemia (LG)-treated bovine aortic endothelial cells (BAECs) \((n = 3)\) incubated for 6 h. Right panel: quantification of the ratio between OGT and OGA. B: Left panel: representative western blot of phospho-threonine OGT and OGT from control or LG-treated BAECs \((n = 3)\) incubated for 6 h. Right panel: quantification of the ratio between phospho-threonine OGT and OGT. C: Left panel: representative western blot of AMPK, P-AMPK, eNOS O-GlcNAcylation, and eNOS from control or hypoglycemia-treated BAECs or AMPK\(\alpha\)-1-knockdown BAECs \((n = 3)\) incubated for 6 h. Right panel: quantification of the ratio of AMPK, P-AMPK, eNOS O-GlcNAcylation, and eNOS. Data are shown as the mean ± SEM and represented as a percentage of control, where the control group was considered to be 100%. ** \(P < 0.01\) vs. control. White = P-AMPK; black = O-GlcNAc.
Figure 3

A

![Graph showing GluAve (mmol/l) vs. Insulin (200 g/U) over time (0-9 h).](image)

B

![Bar chart showing signal intensity of O-GlcNAc, Ser1177, and eNOS over time (0-9 h).](image)

Figure 3
Effect of hypoglycemia on BAEC eNOS O-GlcNAcylation in rat aortae. A: Blood glucose levels in response to insulin-induced hypoglycemia (200 g/U, subcutaneous) in a rat model (n = 5).

B: Left panel: representative western blot of O-linked Glc-NAc, P-eNOS and eNOS from the thoracic aorta of control or insulin-treated rats injected subcutaneously with insulin (n = 5) at 3-9 h after injection. Right panel: quantification of the ratio between O-GlcNAcylation, P-eNOS, and eNOS. Data are shown as the mean ± SEM and represented as a percentage of control, where the control group was considered to be 100%. ** P < 0.01 vs. control. White = control; black = hypoglycemia
Figure 3

A

GluAve (mmol/l)

Insulin (200 g/U)

0 h 3 h 6 h 9 h

B

Hypoglycemia

0 h 3 h 6 h 9 h

O-GlcNAc

Ser1177

eNOS

Signal intensity (a.u.)

0 1 2 3 4

0 h 3 h 6 h 9 h

Time (6 hours)

Figure 3
Effect of hypoglycemia on BAEC eNOS O-GlcNAcylation in rat aortae. A: Blood glucose levels in response to insulin-induced hypoglycemia (200 g/U, subcutaneous) in a rat model (n = 5). B: Left panel: representative western blot of O-linked Glc-NAc, P-eNOS and eNOS from the thoracic aorta of control or insulin-treated rats injected subcutaneously with insulin (n = 5) at 3-9 h after injection. Right panel: quantification of the ratio between O-GlcNAcylation, P-eNOS, and eNOS. Data are shown as the mean ± SEM and represented as a percentage of control, where the control group was considered to be 100%. ** P < 0.01 vs. control. White = control; black = hypoglycemia
Effect of hypoglycemia on O-GlcNAcylation and phospho-eNOS (Ser1177) in His-tagged wild-type (WT)-eNOS and S1177A-eNOS. A: Left panel: representative western blot of His-tagged WT-eNOS-transfected HEK293 cells, O-GlcNAcylation and phospho-eNOS (Ser1177) from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Right panel: quantification of the ratio of O-GlcNAcylation and phospho-eNOS (Ser1177). B: Left panel: representative western blot of WT-eNOS- or S1177A-eNOS-transfected HEK293 cells showing O-GlcNAcylation, phospho-eNOS (Ser1177), phospho-eNOS (Thr495), and phospho-eNOS (Ser633) under normal culture conditions. Right panel: quantification of the ratio of O-linked GlcNAc, phospho-eNOS (Ser1177), phospho-eNOS (Thr495), and phospho-eNOS (Ser633). White = WT-eNOS; black = S1177A-eNOS C: Left panel: representative western blot of S1177A-eNOS-transfected HEK293 cells showing O-GlcNAcylation and phospho-eNOS (Ser1177) in control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Right panel: quantification of the ratio of O-GlcNAcylation and phospho-eNOS (Ser1177). D: Left panel: representative western blot of WT-eNOS- and S1177A-eNOS-transfected BAECs showing O-GlcNAcylation and phospho-eNOS (Ser1177) in control or hypoglycemia treated cells (n = 3) incubated for 6 h. Right panel quantification of the ratio of O-GlcNAcylation and phospho-eNOS (Ser1177). Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. * P < 0.05, *** P < 0.001 vs. control.
Figure 4
Effect of hypoglycemia on O-GlcNAcylation and phospho-eNOS (Ser1177) in His-tagged wild-type (WT)-eNOS and S1177A-eNOS. A: Left panel: representative western blot of His-tagged WT-eNOS-transfected HEK293 cells, O-GlcNAcylation and phospho-eNOS (Ser1177) from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Right panel: quantification of the ratio of O-GlcNAcylation and phospho-eNOS (Ser1177). B: Left panel: representative western blot of WT-eNOS- or S1177A-eNOS-transfected HEK293 cells showing O-GlcNAcylation, phospho-eNOS (Ser1177), phospho-eNOS (Thr495), and phospho-eNOS (Ser633) under normal culture conditions. Right panel: quantification of the ratio of O-linked GlcNAc, phospho-eNOS (Ser1177), phospho-eNOS (Thr495), and phospho-eNOS (Ser633). White = WT-eNOS; black = S1177A-eNOS. C: Left panel: representative western blot of S1177A-eNOS-transfected HEK293 cells showing O-GlcNAcylation and phospho-eNOS (Ser1177) in control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Right panel: quantification of the ratio of O-GlcNAcylation and phospho-eNOS (Ser1177). D: Left panel: representative western blot of WT-eNOS- and S1177A-eNOS-transfected BAECs showing O-GlcNAcylation and phospho-eNOS (Ser1177) in control or hypoglycemia treated cells (n = 3) incubated for 6 h. Right panel quantification of the ratio of O-GlcNAcylation and phospho-eNOS (Ser1177). Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. * P < 0.05, *** P < 0.001 vs. control.
Figure 5
High-pressure liquid chromatography-mass spectrometry (HPLC-MS) and MS/MS Ion Search for enriched eNOS O-GlcNAcylation sites. A: Inset, eNOS protein was recovered from gel. Fractionation by SDS-PAGE revealed a single major eNOS band, which was analyzed by HPLC-MS. B: Left panel: MS/MS Ion Search score of eNOS Ser867 O-GlcNAcylation site. Upper right panel: representative western blot of S867A-eNOS-transfected HEK293 cells showing O-linked GlcNAc from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Lower right panel: quantification of the ratio between control and low glucose treated O-GlcNAcylation. C: Left panel: MS/MS Ion Search score of eNOS Thr866 O-GlcNAcylation site. Upper right panel: representative western blot of T866A-eNOS-transfected HEK293 cells showing O-linked GlcNAc from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Lower right panel: quantification of the ratio between control and low glucose treated O-GlcNAcylation. D: Left panel: representative western blot of T866A-eNOS-transfected BAECs showing O-GlcNAcylation from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Right panel: quantification of the ratio between control and low glucose treated O-GlcNAcylation. Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. ** P < 0.01 vs. control. White = control; black = low glucose (LG).
Figure 5
High-pressure liquid chromatography-mass spectrometry (HPLC-MS) and MS/MS Ion Search for enriched eNOS O-GlcNAcylation sites. A: Inset, eNOS protein was recovered from gel. Fractionation by SDS-PAGE revealed a single major eNOS band, which was analyzed by HPLC-MS. B: Left panel: MS/MS Ion Search score of eNOS Ser867 O-GlcNAcylation site. Upper right panel: representative western blot of S867A-eNOS-transfected HEK293 cells showing O-linked GlcNAc from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Lower right panel: quantification of the ratio between control and low glucose treated O-GlcNAcylation. C: Left panel: MS/MS Ion Search score of eNOS Thr866 O-GlcNAcylation site. Upper right panel: representative western blot of T866A-eNOS-transfected HEK293 cells showing O-linked GlcNAc from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Lower right panel: quantification of the ratio between control and low glucose treated O-GlcNAcylation. D: Left panel: representative western blot of T866A-eNOS-transfected BAECs showing O-GlcNAcylation from control or hypoglycemia-treated cells (n = 3) incubated for 6 h. Right panel: quantification of the ratio between control and low glucose treated O-GlcNAcylation. Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. ** P < 0.01 vs. control. White = control; black = low glucose (LG).
Figure 6
Effect of hypoglycemia on eNOS activity A: NO release in BAEC culture medium in control or hypoglycemia-treated BAECs (n = 3) over 10 h. White = control; black = low glucose (LG).

B: NO release in rat aorta plasma from control or hypoglycemia-treated rat (n = 3) after 6 h. White = control; black = hypoglycemia.

C: Effect of hypoglycemia on L-[14C] citrulline in WT-eNOS- and T866A-eNOS-transfected HEK293 cells. Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control. White = control; black = low glucose (LG).
Figure 6

A

![Graph showing NO release (umol/L) with time points 2 h, 4 h, 6 h, 8 h, 10 h under Low glucose (1 mM) conditions.]

B

![Graph showing NO release (umol/L) under Control and Hypoglycemia conditions with Insulin (200 g/U).]

C

![Western blot analysis of eNOS with bars representing T866A and WT eNOS activities with T866A-eNOS and WT-eNOS data.]

Figure 6
Effect of hypoglycemia on eNOS activity A: NO release in BAEC culture medium in control or hypoglycemia-treated BAECs (n = 3) over 10 h. White = control; black = low glucose (LG).

B: NO release in rat aorta plasma from control or hypoglycemia-treated rat (n = 3) after 6 h. White = control; black = hypoglycemia.

C: Effect of hypoglycemia on L-[14C] citrulline in WT-eNOS- and T866A-eNOS-transfected HEK293 cells. Data are shown as the mean ± SEM and represented as a percentage of the control, where the control group was considered to be 100%. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control. White = control; black = low glucose (LG).